FiercePharma  4 hrs ago  Comment 
The FDA has already struck down two generics of GlaxoSmithKline respiratory blockbuster Advair. But Novartis’ Sandoz is hoping its version can be the one to turn the tide.
FiercePharma  Jun 15  Comment 
The ankylosing spondylitis and psoriatic arthritis markets are growing increasingly crowded, but Novartis now has something not all its rivals can boast: long-term data for its IL-17 med, Cosentyx.
GenEng News  Jun 15  Comment 
Novartis and Verily Life Sciences (formerly Google Life Sciences) have joined the European Investment Fund (EIF) as key investors in a new $300 million fund created by venture capital firm Medicxi to fund late-stage European life sciences...
GenEng News  Jun 13  Comment 
A unanimous U.S. Supreme Court has handed biosimilar developers a key victory that could generate millions in future sales by ruling that they can bring their treatments to market upon FDA approval without waiting an additional six months. The...
FiercePharma  Jun 12  Comment 
Biosim makers scored a big win Monday as the Supreme Court ruled with Sandoz in a much-watched legal dispute with Amgen. The landmark decision, set to define competition in the budding field, allows biosim makers to give marketing notice before...
Clusterstock  Jun 12  Comment 
WASHINGTON — The US Supreme Court on Monday cut the time it will take for copycat versions of biologic drugs — known as biosimilars — to get to the market in a pivotal ruling about an expensive class of medicines that can yield billions of...


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki